1. Home
  2. PACB vs ALLO Comparison

PACB vs ALLO Comparison

Compare PACB & ALLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PACB
  • ALLO
  • Stock Information
  • Founded
  • PACB 2000
  • ALLO 2017
  • Country
  • PACB United States
  • ALLO United States
  • Employees
  • PACB N/A
  • ALLO N/A
  • Industry
  • PACB Biotechnology: Laboratory Analytical Instruments
  • ALLO Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • PACB Industrials
  • ALLO Health Care
  • Exchange
  • PACB Nasdaq
  • ALLO Nasdaq
  • Market Cap
  • PACB 364.2M
  • ALLO 338.9M
  • IPO Year
  • PACB 2010
  • ALLO 2018
  • Fundamental
  • Price
  • PACB $1.20
  • ALLO $1.18
  • Analyst Decision
  • PACB Buy
  • ALLO Strong Buy
  • Analyst Count
  • PACB 10
  • ALLO 10
  • Target Price
  • PACB $2.45
  • ALLO $9.66
  • AVG Volume (30 Days)
  • PACB 6.5M
  • ALLO 2.9M
  • Earning Date
  • PACB 05-08-2025
  • ALLO 05-13-2025
  • Dividend Yield
  • PACB N/A
  • ALLO N/A
  • EPS Growth
  • PACB N/A
  • ALLO N/A
  • EPS
  • PACB N/A
  • ALLO N/A
  • Revenue
  • PACB $154,014,000.00
  • ALLO $22,000.00
  • Revenue This Year
  • PACB $6.13
  • ALLO N/A
  • Revenue Next Year
  • PACB $21.55
  • ALLO $9.07
  • P/E Ratio
  • PACB N/A
  • ALLO N/A
  • Revenue Growth
  • PACB N/A
  • ALLO N/A
  • 52 Week Low
  • PACB $1.06
  • ALLO $1.09
  • 52 Week High
  • PACB $2.72
  • ALLO $3.78
  • Technical
  • Relative Strength Index (RSI)
  • PACB 51.01
  • ALLO 32.42
  • Support Level
  • PACB $1.06
  • ALLO $1.49
  • Resistance Level
  • PACB $1.16
  • ALLO $1.78
  • Average True Range (ATR)
  • PACB 0.06
  • ALLO 0.14
  • MACD
  • PACB 0.01
  • ALLO -0.03
  • Stochastic Oscillator
  • PACB 73.68
  • ALLO 13.04

About PACB Pacific Biosciences of California Inc.

Pacific Biosciences of California Inc is a biotechnology company focused on designing, developing, and manufacturing sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems. It operates in, one reportable segment: the development, manufacturing, and marketing of an integrated platform for genetic analysis. The majority of the company's revenue is derived from Americas, followed by Asia-Pacific and Europe Middle East, and Africa.

About ALLO Allogene Therapeutics Inc.

Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, generated from collaborations and licensing agreements, supports their research and development efforts.

Share on Social Networks: